{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:28:48Z","timestamp":1791181728441,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1997,9,1]],"date-time":"1997-09-01T00:00:00Z","timestamp":873072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[1997,9]]},"DOI":"10.1006\/gyno.1997.4787","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T21:38:48Z","timestamp":1033940328000},"page":"480-486","source":"Crossref","is-referenced-by-count":122,"title":["Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer"],"prefix":"10.1006","volume":"66","author":[{"given":"Elizabeth M.","family":"Swisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet S.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Elbendary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.1997.4787_GO974787C1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"Mcguire","year":"1996","journal-title":"NEJM"},{"key":"10.1006\/gyno.1997.4787_GO974787C2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/gyno.1994.1354","article-title":"Salvage therapy for epithelial ovarian carcinoma","volume":"55","author":"Christian","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C5","first-page":"663","article-title":"Clinical trials with topoisomerase I inhibitors","volume":"19","author":"Burris","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","article-title":"The current status of camptothecin analogues as anti-tumor agents","volume":"85","author":"Slichenmyer","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.1997.4787_GO974787C7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1200\/JCO.1994.12.3.553","article-title":"Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen","volume":"12","author":"Hochster","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.1997.15.1.172","article-title":"Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA-125","volume":"15","author":"Rustin","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C11","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C13","first-page":"139","article-title":"Granulocyte-colony stimulating factor (G-CSF) does not increase the maximum tolerated dose (MTD) in a phase I study of topotecan (T)","volume":"11","author":"Murphy","year":"1992","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C14","first-page":"282","article-title":"Efficacy of topotecan in advanced ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial","volume":"15","author":"Gordon","year":"1996","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C15","first-page":"328","article-title":"Mechanisms of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin","volume":"52","author":"Niimi","year":"1992","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.1997.4787_GO974787C16","first-page":"5919","article-title":"Establishment of a camptothecin analogue (CPT-11) resistant cell line of human non-small cell lung cancer: Characterization and mechanism of resistance","volume":"50","author":"Kanzawa","year":"1990","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.1997.4787_GO974787C17","first-page":"799","article-title":"Establishment of a CPT-11-resistant human ovarian cancer cell line","volume":"14","author":"Kijima","year":"1994","journal-title":"Anticancer Research"},{"key":"10.1006\/gyno.1997.4787_GO974787C18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0090-8258(90)90115-2","article-title":"Hexamethylmelamine as a single second-line agent in ovarian cancer","volume":"36","author":"Manetta","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/gyno.1993.1255","article-title":"Hexamethylmelamine\/altretamine as second-line therapy for epithelial ovarian cancer","volume":"51","author":"Moore","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000226835","article-title":"Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a second-line treatment in ovarian cancer","volume":"47","author":"Eckhardt","year":"1990","journal-title":"Oncology"},{"key":"10.1006\/gyno.1997.4787_GO974787C22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.1994.12.1.60","article-title":"Oral etoposide is active against platinum-resistant ovarian cancer","volume":"12","author":"Hoskins","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.1992.10.2.243","article-title":"Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C24","first-page":"47","article-title":"Ifosfamide in the treatment of ovarian cancer","volume":"23","author":"Markman","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C25","first-page":"72","article-title":"Gemcitabine in cisplatin-resistant ovarian cancer","volume":"23","author":"Lund","year":"1996","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.1997.4787_GO974787C26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/gyno.1997.4622","article-title":"Phase II study of 96-hr continuous infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer","volume":"65","author":"Fleming","year":"1997","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825897947879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825897947879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T01:54:20Z","timestamp":1557280460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825897947879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,9]]}},"alternative-id":["S0090825897947879"],"URL":"https:\/\/doi.org\/10.1006\/gyno.1997.4787","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[1997,9]]}}}